Julio Castro. Oryzon Genomics

Colaboración Público-Privada para el descubrimiento de Fármacos
en España
Santiago de Compostela
19 de Noviembre de 2009
R&D focused
Oryzon is a biomarker and
target discovery company
with IVD & drugs for
oncology and
neurodegenerative diseases
Robust financial situation
 Venture backed from 2003
 >22 M € fresh cash-in achieved in 2008
 5 M € income in 2007 & 6.7M € in 2008
 5 consecutive years on net profits
(2004-2008)
Fast growing commitment
 acquisition of Crystax Pharmaceuticals
becoming the biggest drug-discovery
biotech in oncology in Spain
 more than 80 scientist
(40 Ph.D + 20 BSCi)
 >22 M € R&D investment in 4 years
Product oriented platforms
DISCOVERY
DISCOVERY
PLATFORM
POTENTIAL
BIOMARKERS/
TARGETS
THERAPY
FUNCTIONAL
VALIDATION
PLATFORM
PROTEOMIC
VALIDATION
PLATFORM
VALIDATED
TARGETS
ANTIBODY
DEVELOPMENT
PLATFORM
STRUCTURAL
GENOMICS
PLATFORM
THERAPEUTIC
BIOLOGICALS
SMALL
MOLECULES
DIAGNOSTICS
VALIDATED
BIOMARKERS
IVD
KITS
Internal Drug Discovery Capabilities (I)
B2D2TM
Biology
Virtual
Screening
Fragment
Screening
Crystallization
NMR Methods
Internal Drug Discovery Capabilities (II)
Calorimetry
Cellular assays
In vitro Binding
SAR
Energetics
Potency in cells
X-ray
Biomarkers
17AAG
Biacore
RU
CRY0165
C
Slow diss.
RU
Fast diss.
14
12
12
GADPH
10
10
8
8
CDK4
Her2
Hsp70
Response
Response
c-Raf1
6
4
2
0
0
-2
-2
Medicinal
Chemistry
20
50
80
Time
Mechanism
4
2
-10
Structure-based
drug design
6
110
140-20
s
Kinetics
0
20
40
Time
60
80
s
Small molecules Research at Oryzon: A young and
successful enterprise
Early 2008
Target elucidation
Mid 2008
Start of the Medicinal Chemistry Effort
End 2008
Crystax acquisition
Today…..
Full drug discovery engine……over 30 people
Fragment screening capabilities
HTS facilities
Biochemical assays labs
Medicinal Chemistry
Pharmacokinetics and metabolism
In vivo Pharmacology
Toxicology
5 Drug Discovery programs in progress
EL EXITO DE LAS COLABORACIONES ES CLAVE PARA SER UNA BIOTECH EXITOSA